Forian Revenue Jumps 56 Percent in Q2

Forian (NASDAQ:FORA) reported robust Q2 2025 results, with GAAP revenue surging 56% year-over-year to $7.48 million, exceeding analyst estimates, and GAAP EPS meeting expectations at $0.01, reversing a prior-year loss. The significant top-line growth and improved profitability, including positive net income of $0.22 million and a 656% increase in adjusted EBITDA, were largely driven by strategic contract renewals and the successful integration of the Kyber Data Science acquisition. With $35.6 million in cash, the company is focused on scaling and expanding its recurring revenue base, though investors will monitor the recurring revenue mix and a September 2025 convertible note maturity against reaffirmed FY2025 guidance.

Analysis

Forian Inc. (NASDAQ:FORA) reported a robust second quarter for fiscal year 2025, demonstrating a significant operational turnaround and growth acceleration. GAAP revenue surged 56% year-over-year to $7.48 million, outperforming analyst estimates of $7.17 million, driven by strategic contract renewals and the integration of the Kyber Data Science acquisition. The company achieved a key profitability milestone, posting GAAP net income of $0.22 million and an EPS of $0.01, a stark reversal from the $2.55 million net loss and $(0.08) per-share loss in the prior-year quarter. Non-GAAP adjusted EBITDA showed dramatic improvement, rising 656% to $0.59 million; however, this figure was substantially influenced by a $0.66 million adjustment for non-cash stock-based compensation. The company's balance sheet appears solid with $35.6 million in cash and equivalents, providing a buffer as it manages a $6.80 million convertible note maturing in September 2025. Management reaffirmed its full-year 2025 guidance, with revenue projected between $28 million and $30 million and a wide adjusted EBITDA range from a $1.0 million loss to a $1.0 million gain, reflecting ongoing integration investments and uncertainty in the pace of contract growth.

Key Decisions for Investors

• Given the strong revenue beat and shift to GAAP profitability driven by the Kyber acquisition, investors may see this as an inflection point, warranting a re-evaluation of Forian's growth trajectory in the healthcare and financial data analytics space.
• It is critical to scrutinize the quality of earnings by looking beyond the headline adjusted EBITDA, as it was significantly impacted by non-cash stock compensation, and instead focus on sustainable cash flow generation.
• Investors should closely monitor two key factors: the company's ability to convert one-year SaaS contracts into a stable, recurring revenue base and its capital management strategy concerning the $6.80 million convertible note maturing in September 2025.